VEA
PTGX icon

Virtus ETF Advisers’s Protagonist Therapeutics PTGX Stock Holding History

Virtus ETF Advisers’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,761
Closed -$68K – 704
2024
Q4 		$68K Sell
1,761
-919
-34% -$40.1K 0.03% 396
2024
Q3 		$121K Buy
2,680
+45
+2% +$1.82K 0.06% 352
2024
Q2 		$91.3K Sell
2,635
-1,540
-37% -$45.1K 0.04% 353
2024
Q1 		$121K Sell
4,175
-282
-6% -$7.67K 0.06% 346
2023
Q4 		$102K Buy
4,457
+1,017
+30% +$17.8K 0.06% 349
2023
Q3 		$57.4K Sell
3,440
-346
-9% -$6.71K 0.03% 407
2023
Q2 		$105K Sell
3,786
-6,500
-63% -$163K 0.06% 360
2023
Q1 		$237K Sell
10,286
-3,949
-28% -$66.3K 0.13% 294
2022
Q4 		$155K Sell
14,235
-2
-0% -$17 0.08% 335
2022
Q3 		$120K Buy
14,237
+108
+0.8% +$1.02K 0.05% 399
2022
Q2 		$112K Buy
14,129
+8,913
+171% +$108K 0.04% 402
2022
Q1 		$124K Sell
5,216
-305
-6% -$8.59K 0.06% 258
2021
Q4 		$189K Buy
5,521
+351
+7% +$11.1K 0.07% 232
2021
Q3 		$92K Sell
5,170
-271
-5% -$11.6K 0.04% 386
2021
Q2 		$244K Sell
5,441
-8,905
-62% -$294K 0.1% 218
2021
Q1 		$372K Buy
14,346
+244
+2% +$6.17K 0.16% 194
2020
Q4 		$284K Sell
14,102
-4,946
-26% -$106K 0.12% 238
2020
Q3 		$372K Sell
19,048
-2,591
-12% -$48.6K 0.2% 177
2020
Q2 		$382K Buy
+21,639
New +$271K 0.18% 218

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Virtus ETF Advisers's PTGX Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Protagonist Therapeutics (PTGX) in Q1 2025, closing a stake of 1,761 shares — an estimated $68K sold.

Virtus ETF Advisers first reported a position in PTGX in Q2 2020 and held it in 19 quarters. The position peaked at $382K in Q2 2020. 275 funds tracked by Wall St. Rank hold PTGX as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Protagonist Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 1,761 Protagonist Therapeutics shares in Q1 2025, an estimated $68K.
  • Virtus ETF Advisers first reported a position in Protagonist Therapeutics in Q2 2020 and held it in 19 quarters.
  • Virtus ETF Advisers's Protagonist Therapeutics position peaked at $382K in Q2 2020.
  • 275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.